LOL Tweets they don't pay taxes, coming from a guy that does not pay taxes. Ironic don't you think...
Last chance to get in under $1,000.
Shorts be like...
All you bashers out there I wonder if you really have the nuts to short it !
There's my $988 "inflection" folks. Stays below? Going to $899. Stays above? Going to $1065.
ONLY trade the info/technicals folks! Enjoy.
Why is it down? They told me this was a good one.
So, if the premarket data was on the upside, how could this be floundering right now?
Stephen Alan "Steve" Wynn, (born January 27, 1942). Wynn has publicly self-identified as a supporter of the Democratic Party in the United States.
Walls street controllers trying their best to continue to prop this overvalued stock up... who’s gonna win? Bulls or Bears. My money is on the bears finally taking this bloated internet retailer down for awhile
Would you believe that Amazon made only 4B profit since 1997 and that Walmart made 16B profit just in 2016 alone? I hate Walmart but I am just saying AMZN is becoming a big bubble.
LOAD UP SOME IGXT MAJOR BREAKOUT IMMINENT ... IGXT (MC $50 M) NDA filing for BLOCKBUSTER thin-flim Cialis (BETTER THAN Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!
2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL
MarketCap $50 Million Cash ~$12 Million (including convertible debt) =cash untill 2021+ Price: 0.80
NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July NDA resubmission for Rizaport (migraine) in early Q3 Partnership for Tadalafil in 2H 2017
IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.
Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.
IntelGenx has multi-faceted BD approach for its oral films
With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
Short squeeze in process. Then start again, LOL. Beautiful, if you can time it right a lot of money can be made.
What an opportunity. Will pop back to 1,000 in no time.
if you can see level 2 before early trading it is going up Big Time...
Amazon just traded like NASDAQ today, if NSDAQ goes up AMZN goes up.
1000 by Thursday
if you missed buying Amazon at 976.00 I feel bad for you....